Net sales for the first half of FY2026 increased year-on-year, and the full-year earnings forecast has been revised upward. Core areas\u2014renal\/dialysis and infusion\u2014performed solidly. Cost of goods sold is expected to worsen in the second half as the impact of sharply rising material prices in the first half becomes apparent. R&D expenses are expected to increase, but overall profits have been revised upward. Interim dividend is 46 yen per share, and a progressive dividend policy will continue through FY2030.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4538","jir_company_name":"Fuso Pharmaceutical Industries,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4538-20261111-03.pdf","jir_short_summary":"Net sales for the first half of FY2026 increased year-on-year, and the full-year earnings forecast has been revised upward. Core areas\u2014renal\/dialysis and infusion\u2014performed solidly. Cost of goods sold is expected to worsen in the second half as the impact of sharply rising material prices in the first half becomes apparent. R&D expenses are expected to increase, but overall profits have been revised upward. Interim dividend is 46 yen per share, and a progressive dividend policy will continue through FY2030.","jir_summary":"### Overview of Results\nFor the first half of FY2026, net sales were 32,395 million yen, operating income was 1,743 million yen, ordinary income was 1,434 million yen, and interim net income was 1,041 million yen. Net sales increased by 3.7% year-over-year, and all profit indicators achieved significant increases. Based on first-half results, the full-year forecasts have been revised upward to net sales of 64,800 million yen, operating income of 2,000 million yen, ordinary income of 1,500 million yen, and net income attributable to owners of parent of 1,500 million yen.\n\n### Outlook and Factors\nStrong performance of products such as Rixell, Celnilton, and Dopacol is expected to continue. However, the impact of rising raw material prices due to Middle East conditions is expected to become apparent in the second half, leading to a deterioration in cost ratios. R&D expenses are expected to increase, but the full-year forecast has been revised upward based on first-half results. The interim dividend will be 45 yen, and the year-end dividend will be increased by 1 yen to 46 yen, with a policy to continue progressive dividends through FY2030.","jir_financial_highlights":"Net Sales: 32,395 (Year-over-Year +3.7%)\nOperating Income: 1,743 (Year-over-Year +39.7%)\nOrdinary Income: 1,434 (Year-over-Year +26.8%)\nInterim Net Income: 1,041 (Year-over-Year +25.2%)\nFull-Year Net Sales: 64,800 (+893)\nFull-Year Operating Income: 2,000 (+400)\nFull-Year Ordinary Income: 1,500 (+400)\nFull-Year Net Income Attributable to Owners of Parent: 1,500 (+711)","jir_category":"","jir_hashtags":"#FusoPharmaceuticalIndustries, #EarningsPresentation, #FirstHalfResults, #MidTermPlan, #ResearchAndDevelopment","jir_key_figures":"Net Sales: 32,395 million yen (Year-over-Year +3.7%)\nOperating Income: 1,743 million yen (+39.7%)\nOrdinary Income: 1,434 million yen (+26.8%)\nInterim Net Income: 1,041 million yen (+25.2%)\nFY2026 Full-Year Net Sales: 64,800 million yen (+893 vs. previous) forecast","jir_meta_title":"Fuso Pharmaceutical Industries,Ltd. Supplementary Materials for FY2026 First Half Financial Results\uff5cUpward Revision of Sales and Profits","jir_meta_description":"Supplementary materials for Fuso Pharmaceutical Industries,Ltd.'s FY2026 first half financial results. Net sales of 32,395 million yen and operating income of 1,743 million yen, with an upward revision to full-year outlook and dividend policy explained. Also covers the impact of rising raw material costs and future R&D expenditure trends.","jir_og_title":"Fuso Pharmaceutical Industries,Ltd.\uff5cSupplementary Materials for FY2026 First Half Financial Results","jir_og_description":"Summary of Fuso Pharmaceutical Industries,Ltd.'s FY2026 first half results, upward revision to full-year outlook, and dividend policy highlights.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"[{x:'FY2024',y:27800},{x:'FY2025',y:31350},{x:'FY2026 H1',y:32395},{x:'FY2026 Full-Year Forecast',y:64800}]\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"[{x:'FY2024 H1',y:5127},{x:'FY2025 H1',y:5800},{x:'FY2026 H1',y:1743}]\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Trend\", \"jir_chart_json_data\": \"[{x:'FY2024',y:20.4},{x:'FY2025',y:22.4},{x:'FY2026 H1',y:26.9}]\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Key Segment\", \"jir_chart_json_data\": \"[{segment:'Renal & Dialysis',value:32895},{segment:'Infusion',value:12000},{segment:'Generics',value:6000}]\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Revised Full-Year Forecast and Previous Forecast\", \"jir_chart_json_data\": \"[{item:'Net Sales',previous:'63,200',revised:'64,800'},{item:'Operating Income',previous:'1,600',revised:'2,000'},{item:'Ordinary Income',previous:'1,100',revised:'1,500'}]\"}]","ir_related_company":57749,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149179","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n